Proliferative Vitreoretinopathy (PVR) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Proliferative vitreoretinopathy (PVR) is the most common cause of failure of rhegmatogenous retinal detachment repair. It is characterised by the growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retinal surface and intraretinal fibrosis. Contraction of these membranes can cause the retina to redetach and transform a rhegmatogenous detachment into a tractional detachment. It is most common as a clinical complication of surgical procedures to correct rhegmatogenous retinal detachments, which are detachments that follow the formation of a retinal tear or hole. Tractional forces produced by the scar tissue-like PVR membranes can be transmitted to the retina, resulting in complete retinal detachment, retinal degeneration, and permanent blindness. PVR has also been reported to be common following posterior segment procedures or disorders such as giant retinal tears, macular relocation surgery, tumors endoresection, and chip implantation. PVR has been developed in 29% of cytomegalovirus retinitis-related retinal detachment patients infected with the human immunodeficiency virus.
·
PVR is reported to account for 5-10% of all
rhegmatogenous retinal detachments (RRD) and is the most common cause of
surgery failure for RRD.
Thelansis’s “Proliferative
Vitreoretinopathy (PVR) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Proliferative
Vitreoretinopathy (PVR) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Proliferative Vitreoretinopathy (PVR) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Proliferative Vitreoretinopathy (PVR) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment